FDA approval of Crinetics Pharmaceuticals’ Palsonify makes it the first oral first-line therapy for acromegaly, a rare endocrine disorder. The once-daily pill will compete with blockbuster acromegaly drugs from Novartis and Ipsen that are administered as injections.
Israeli startup Chiasma in the midst of a hefty fundraise: It’s raised $33.8 million of a proposed $56.3 million round, according to regulatory filings. This comes as a timely vote of confidence – the company was expecting a $595 million deal that fell through over the summer. Chiasma’s lead product, oral octreotide, is being developed […]
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.